Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arista Financial Corp.ARST · Entity 163118 | Interim CFO | October 01, 2018 | October 09, 2018 |
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Interim CFO | December 23, 2023 | December 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arista Financial Corp.
Report date October 01, 2018 · Filed October 09, 2018
This filing explicitly reported no securities owned.
InMed Pharmaceuticals Inc.
Report date December 23, 2023 · Filed December 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2028-12-22 | Direct | 31,400 |
Reported balance
After 2023-12-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-23 · Grant · Acquired 30,000 · Balance 31,400 F1: The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month). |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2023 Filed Dec 26, 2023 18:08 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001213900-23-098492 · ownership.xml · derivative · entry 1 Tegge Jonathan · CIK 0001755310 · Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,400 Underlying: Common shares · 30,000 shares Expires 2028-12-22 F1 · derivative.exercise_date: The options were granted on 12/23/2023 and will vest in equal installments monthly over 36 months (1/36 per month). Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 22:04 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,400 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-22-080971 · ownership.xml · derivative · entry 1 Tegge Jonathan · CIK 0001755310 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common shares · 1,400 shares Expires 2027-12-15 F1 · derivative.exercise_date: Vesting 1/12 per month, in arrears, for 12 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.